FTC Will Push To Block $3.1B CSL-Talecris Merger
Federal Trade Commission staff members oppose blood plasma-derived therapeutics company CSL Ltd.'s proposed $3.1 billion acquisition of rival Talecris Biotherapeutics and have asked the agency to block the deal, CSL has...To view the full article, register now.
Already a subscriber? Click here to view full article